APG-157

DRUG5 trials

Sponsors

Aveta Biomics, Inc., Elizabeth J Franzmann

Conditions

GlioblastomaGlioblastoma MultiformeGliomaHead and Neck (HNSCC)Head and Neck CancerOral Carcinoma in SituOral CavityOral Cavity Carcinoma

Phase 1

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

RecruitingNCT06011109

Aveta Biomics, Inc.Glioblastoma Multiforme, Glioma

Start: 2023-12-13End: 2027-06-30Target: 30Updated: 2026-06-08

Phase 2

Safety and Efficacy of APG-157 in Head and Neck Cancer

Active, not recruitingNCT05312710

Aveta Biomics, Inc.Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx

Start: 2022-04-22End: 2026-12-01Target: 24Updated: 2026-01-16

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

RecruitingNCT05865028

Elizabeth J FranzmannOral Carcinoma in Situ, Oral Cavity Dysplasia, Oropharyngeal Dysplasia

Start: 2023-05-24End: 2028-05-24Target: 32Updated: 2026-01-14

Phase 3

APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruitingNCT07667296

Aveta Biomics, Inc.Head and Neck Cancer, Head and Neck (HNSCC), Oral Cavity +4

Start: 2026-07-01End: 2032-12-01Target: 826Updated: 2026-07-01

Unknown Phase

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Aveta Biomics, Inc.Glioblastoma, Glioblastoma Multiforme

Updated: 2024-08-09

Related Papers

Preliminary results from a phase IIa trial of APG-157 in oral cavity and oropharyngeal dysplasia.

Journal of Clinical Oncology2025-05-28

Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial.

Journal of Clinical Oncology2025-05-28